Sentence examples for developments can be explained from inspiring English sources
The paper hypothesizes that the differences in outdoor temperatures within and between residential developments can be explained by the impact of design-related variables on the overall environment.
As social integration is crucial for an apprentice's socialization and learning, it is important to know how social integration develops and changes during organizational entry and how this development can be explained by pre-entry factors related to the school context or to effects of the company's onboarding strategies.
First, it considers how the history of innovation studies for sustainable development can be explained as a process of linking broader analytical frameworks to successively larger problem framings.
Many non-host selective microbial phytotoxins are known to induce a generation of ROS and in many cases, disease symptom development can be explained by this mechanism (Heiser et al. [1998]).
The finding that the loss of EF-G1 does not affect eye development can be explained if Drosophila EF-G2 assumes the function of elongation in the eye.
That SR 25989, which potentially inhibits angiogenesis, did not alter tumour growth and lymph node development can be explained by the high vascularisation of the foot pad.
This development can be explained by the fact that less young workers are entering the construction industry and, at the same time, the baby boom cohort moves towards the retirement age [ 2, 3].
The multifunctionality of the OsGELP family in rice, as well as in other land plant species, their diverse roles in different aspects of plant growth and development can be explained by the complexity and diversity of the genes at the structural level.
For example, low stability of mRNA among genes in the functional category of 'Regulation of transcription' and 'Development' can be explained by the low number of exon junctions per ORF length and high number of ARE4 and PUF in 3′-UTR and CpG in 5′-UTR (Fig. 3C).
The lack of performance experienced by several colloidal drug carriers during the preclinical and clinical development processes can be explained by inadequate pharmacokinetic/biodistribution profiles and/or unacceptable toxicities.
